Table 2. Top-ranked signaling pathways exhibiting a significant differential signaling domain distribution between functional DNA methylation and SCN alterations based on a meta-analysis over 10 cancer types.
| Signaling pathway | BLCA | BRCA | COAD | HNSC | KIRC | LIHC | LUAD | LUSC | THCA | UCEC | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GPCR | 0.103 | 0.024 | 0.116 | 4e-05 | 2e-04 | 0.022 | 0.031 | 0.002 | 1 | 0.116 | 7e-10 |
| IMMUNE SYSTEM | 0.006 | 1 | 0.017 | 0.117 | 0.001 | 0.118 | 8e-04 | 0.176 | 0.009 | 0.016 | 2e-08 |
| WNT | 0.061 | 0.016 | 0.006 | 0.015 | 0.008 | 0.011 | 0.008 | 0.035 | 0.1 | 1 | 8e-08 |
| CHEMOKINE | 0.05 | 0.005 | 0.611 | 0.001 | 9e-04 | 0.053 | 0.5 | 0.133 | 0.05 | 0.455 | 2e-06 |
| HEMOSTASIS | 0.045 | 4e-05 | 0.551 | 0.004 | 0.072 | 0.154 | 0.038 | 0.498 | 1 | 0.022 | 2e-06 |
| FOCAL ADHESION | 0.331 | 0.038 | 0.261 | 0.056 | 0.095 | 0.182 | 0.083 | 0.005 | 1 | 0.006 | 1e-04 |
| JAK_STAT | 0.133 | 0.011 | 0.035 | 0.119 | 0.017 | 0.111 | 0.22 | 0.192 | 0.1 | 1 | 5e-04 |
| TOLL_LIKE RECEPTOR | 1 | 0.059 | 1 | 0.048 | 0.005 | 0.083 | 0.045 | 0.091 | 1 | 0.029 | 0.001 |
| LIPID METABOLISM | 0.03 | 0.013 | 0.082 | 0.154 | 1 | 0.2 | 0.015 | 1 | 0.044 | 1 | 0.003 |
| DIABETES | 0.1 | 0.004 | 0.429 | 0.1 | 1 | 0.012 | 0.077 | 0.6 | 1 | 1 | 0.012 |
| PDGF | 1 | 0.032 | 0.029 | 0.045 | 1 | 0.091 | 0.308 | 0.333 | 1 | 0.031 | 0.014 |
P-values for each cancer type were calculated using a one-tailed Fisher's exact test. A meta-analysis P-value was calculated for each signaling pathway using Fisher's combined test.